Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-23
2010-02-23
Padmanabhan, Sreeni (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S300100, C548S335100
Reexamination Certificate
active
07666893
ABSTRACT:
A method for treatment of multiple sclerosis and other neurodegenerative diseases, disorders or conditions. An alkyl ester of imidazole carboxylic acid, preferably methyl 4-imidazolecarboxylate, is administered in a therapeutic amount. It is hypothesized that the alkyl ester of imidazole carboxylic acid serves to restore and/or maintain the intracellular/extracellular osmolyte gradient in the central nervous system (CNS). The methyl 4-imidazolecarboxylate may be administered transdermally, using PLO gel or other suitable transdermal carrier. The compound may also be administered orally, inhaler or by injection. The treatment is advantageously performed on a three day cycle, with a period of two days intervening between each day on which the compound is administered. Dosage ranges may be from about 0.01 mcg to about 3.0 mcg, with dosages in the range from about 0.1 mcg to about 0.2 mcg in generally preferred when using transdermal administration.
REFERENCES:
patent: 4055573 (1977-10-01), Mendelson
patent: 6277402 (2001-08-01), DeLack
patent: 6359145 (2002-03-01), Terasaka et al.
patent: 6426360 (2002-07-01), Weier et al.
patent: 6596738 (2003-07-01), Terasaka et al.
patent: 6617324 (2003-09-01), Naraian et al.
Alcazar et al. (1998). Induction of apoptosis by cerebrospinal fluid from patients with primary-progressive multiple sclerosis . . . Neuroscience Letters, 255, pp. 25-78.
Aulkemeyer et al. (2000). The small sodium-channel blocking factor in cerebrospinal fluid of multiple sclerosis patients . . . Journal of Neurological Science, 172(1), pp. 49-54.
Baslow, M.H. (1998). Function of the N-acetyl-L-histidine system in the vertebrate eye. Journal of Molecular Neuroscience, 10(3), pp. 193-208.
Behan et al. (2002) The pathogenesis of multiple sclerosis revisited. J R College of Physicians Edinb, 32, pp. 244-265.
Blaustein, M.P. (1975). Effects of potassium, veratridine, and scorpion venom on calcium accumulation and transmitte . . . Journal of Physiology, 247(3), pp. 617-655.
Carvounis, C.P. (1985). Importance of amino acids on vasopressin-stimulated water flow. Journal of Clinical Investigation, 76(2), pp. 779-788.
Chua et al. (2002). MRI findings in osmotic myelinolysis. Clinical Radiology, 57(9), pp. 800-806.
Cid et al. (2002). Neronal apoptosis induced by cerebrospional fluid from multiplsclerosis patients . . . Journal of Neurological Science, 193(2), pp. 103-109.
Davies et al. (1998). Hypoosomolarity induces an increase of extracellular N-acetylaspartate concentrationin the rat striatum. Neurochemical Research, 23(3), pp. 1021-1025.
Davis et al. (2002). Glial fibrillary acidic portein in late life major depressive disorder . . . Journal of Neurology Neurosurgery Psychiatry, 73(5), pp. 556,560.
Fields, R.D. (2004). The other half of the brain: Mounting evidence suggests that glilal cells, overlooked for half a century, may . . . Scientific Amercian, pp. 54-61.
Gehl et al. (2004). Biosynthesis of NAAG by an enzyme-mediated process in rat central nervous system neurons and glia. Journal of Neurochemistry, 90(4), pp. 989-997.
Hertz et al. (2004). Astrocytic adrenoceptors: A major drug target in neurological and psychiatric . . . Current Drug Targets CNS Neurological Disorders, 3(3), pp. 239-267.
Huang et al. (2000). Transport of N-acetylasparate by the Na(+)-dependent high-affinity dicarboxylate . . . Journal of Pharmacology Experimental Therapies, 295(1), pp. 392-403.
Kashon et al. (2004). Associations of cortical astrogliosis with cognitive performance and demetia . . . Journal of Alzheimer's Disease, 6(6), pp. 595,604; discussion 673-681.
Kiline et al. (2002). Osmotic myelinolysis in a normonatremic patient. Acta Neurology Belgium, 102(2), pp. 87-89.
Koller et al. (1996). Cerebrospinal fluid from multiple sclerosis patients inactivates neuronal Na+ current. Brain, 119(Pt 2), pp. 457-463.
Mews et al. (1998). Oligodendrocyte and axon pathology in clinical silent multipel sclerosis lesions. Multiple Sclerosis Journal, 4(2), pp. 55-62.
Oliveira et al. (2004). Alterations in the central vasopressin and oxytocin axis after lesion of a brina osmotic sensory region. Brain Research Bulletin, 63(6), pp. 515,520.
Perea et al. (2005). Synaptic regulation of the astrocyte calcium signal. Journal of Neurl Transmission, 112(1), pp. 127-135.
Ramsey et al. (1984). The defence of plasma osmolaity. Journal of Physiology (Paris), 79(6), pp. 416-420.
Sager et al. (1999). Astroglia contain a specific transport mechanism for N-acetyl-L-aspartate. Journal of Neurochemistyr, 73(2), pp. 807-811.
Schiepers et al. (1997). Positron emission tomography, magnetic resonance imaging and proton NMR . . . Multiple Sclerosis Journal, 3(1), pp. 8-17.
Sharma et al. (1992). Histamine modulates heat stress-induced changes in blood-brain barrier permeability, cerebral blood flow . . . Neurosceince, 50(2), pp. 445, 454.
Simard et al. (2004). The nerobiology of glia in the context of waer and ion homeostatis. Neuroscience, 129(4), pp. 877-896.
Tateishi et al. (2006). S100B: astrocyte specific protein. Nihon Schinkei Seishin Yakurigaku Zassi, 26(1), pp. 6-11.
Vivekanandhan et al. (2005). Adenosine deaminase and 5′nuclotidiase activities in peripheral blood T cells . . . Neurochemistry Research, 30(4), pp. 453-456.
Williamson et al. (1988). Calcium-dependent release of N-acetylaspartylglutamate from retinal nerons upon depolarization. Brain Research, 475(1), pp. 151-155.
Hathaway Todd N.
MedDEV Inc.
Padmanabhan Sreeni
Pihonak Sarah
LandOfFree
Method for treatment of neurodegenerative disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treatment of neurodegenerative disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treatment of neurodegenerative disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4165359